PRRT as neoadjuvant treatment in NET

Recent Results in Cancer Research

Volumn 194, Issue , 2013, Pages 479-485

  Sowa Staszczak, Anna ^a   Hubalewska Dydejczyk, Alicja ^a   Tomaszuk, Monika ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOTOXIC AGENT; FLUOROURACIL; KI 67 ANTIGEN; LUTETIUM TETRAXETAN OCTREOTIDE[3 TYROSINE] LU 177; UNCLASSIFIED DRUG; YTTRIUM TETRAXETAN OCTREOTIDE[3 TYROSINE] Y 90;

BIOLOGICAL THERAPY; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER SURGERY; DISEASE ASSOCIATION; DRUG HALF LIFE; DRUG RESPONSE; DUODENUM TUMOR; EXTERNAL BEAM RADIOTHERAPY; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LAPAROTOMY; LIVER METASTASIS; LIVER RESECTION; LYMPH NODE METASTASIS; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NEUROENDOCRINE TUMOR; PANCREAS CANCER; PANCREATIC NEUROENDOCRINE TUMOR; PANCREATICODUODENECTOMY; PRIORITY JOURNAL; REVIEW; TREATMENT DURATION; TREATMENT PLANNING; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR REGRESSION; TUMOR VOLUME;

EID: 84867037559     PISSN: 00800015     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-642-27994-2_27     Document Type: Review

References (10)

1. Barber TW, Hofman MS, Thomson BN et al (2012) The potential for induction peptide receptor chemoradionuclide therapy to render inoperable pancreatic and duodenal neuroendocrine tumors resectable. Eur J Surg Oncol 38:64-71
2. Cremonesi M, Ferrari M, Bodei L et al (2006) Dosimetry in peptide radionuclide receptor therapy: A review. J Nucl Med 47:467-1475
3. Faiss S, Pape UF, Bohming M et al (2003) Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors - the international lanreotide and interferon alfa study group. J Clin Oncol 21:2689-2696 (Pubitemid 46606312)
4. Kaemmerer D, Prasad V, DaffnerWet al (2009) Neoadjuvant peptide receptor radionuclide therapy for an inoperable neuroendocrine pancreatic tumor. World J Gastroenterol 15:5867-5870
5. Kazanjian KK, Reber HA, Hines OJ (2006) Resection of pancreatic neuroendocrine tumors: Results of 70 cases. Arch Surg 141:765-769 (Pubitemid 44268515)
6. Nomura N, Fujii T, Kanazumi N et al (2009) Nonfunctioning neuroendocrine pancreatic tumors: Our experience and management. J Hepatobiliary Pancreat Surgery 16:639-647
7. Oberg K, Kvols L, Caplin M et al (2004) Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Ann Oncol 15:966-973 (Pubitemid 39004355)
8. Rinke A, Muller HH, Schade- Brittinger C et al (2009) Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumor: A report from the PROMID study group. J Clin Oncol 27:4656-4663
9. Sowa-Staszczak A, Pach D, Chrzan R et al (2011) Peptide receptor radionuclide therapy as a potential tool for neoadjuvant therapy in patients with inoperable neuroendocrine tumors (NETs). Eur J Nucl Med Mol Imaging 38:1669-1674
10. Stoeltzing O, Loss M, Huber M et al (2010) Staged surgery with neoadjuvant 90Y-DOTATOC therapy for down-sizing synchronous bilobular hepatic metastases from a neuroendocrine pancreatic tumor. Langenbecks Arch Surg 395:185-192